First part of a 2-part interview with Stephen Strickland, MD, MSCI, director of leukemia research for Sarah Cannon Research ...

Researchers will use Cellply's VivaCyte platform to conduct single-cell analyses of NK cells and evaluate their ability to treat the bone marrow cancer.

Swedish cancer patients treated with CAR T-cell therapy show better survival rates and fewer side effects than seen in ...

When the Lupus Research Alliance formed in 1999, treatment options for the condition were scarce. Doctors relied on a ...

The first CAR-T cell therapy was developed and approved by the FDA in 2017 to treat relapsed or refractory B-cell precursor ...

IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment.

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

Allogeneic hematopoietic stem-cell transplantation (HSCT ... them with marnetegragene-autotemcel (marne-cel), a gene therapy of autologous CD34+ hematopoietic stem cells transduced with a self ...